Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

by divibasicbldev | Mar 24, 2025 | Press Releases

— Conference taking place on March 27-29, 2025 in New Orleans — — CAGLA NeauxCancer Conference is a leading global forum in oncology — MIAMI, March 24, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA)...

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

by divibasicbldev | Feb 5, 2025 | Press Releases

SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT’s) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ:...

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

by divibasicbldev | Jan 14, 2025 | Press Releases

— Interim data from Cohort 4 expected Q1 2025 — MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a...

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

by divibasicbldev | Nov 20, 2024 | Press Releases

— SRC recommended that the trial escalate to the next dose level of 15mg capsule — — No dose-limiting toxicities (DLTs) observed to date — — No rash observed to date — MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) — Pasithea...

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

by divibasicbldev | Sep 26, 2024 | Press Releases

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment...